ReviewDie Ophthalmologie2026
[Telemetric self-monitoring of intraocular pressure: from vision to reality? : Insights from the EyeMate-SC sensor].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EyeMate-SC (G-Metrics GmbH, Hanover, Germany) is a permanently implantable microsensor positioned in the suprachoroidal space for telemetric, high-frequency self-measurement of intraocular pressure (IOP), with measurements transmitted to the treating ophthalmologist via an external reading device.
objectiveThe aim of this review is to summarize the evidence regarding the safety of the implant, agreement of measurements with Goldmann applanation tonometry (GAT), patient adherence and acceptance, and the potential for capturing IOP fluctuations. MATERIAL AND
methodsThis review includes 24 patients with open-angle glaucoma who received an EyeMate-SC sensor as part of a nonpenetrating glaucoma surgery and were followed for 3 years within the ARGOS-SC01 study and its follow-up study, ARGOS-SC01_FU.
resultsImplantation was successfully performed in all cases without complications. Over the observation period 15 moderate adverse events occurred beyond the early postoperative phase, of which one case was possibly related to the sensor. The device demonstrated long-term positional stability without dislocation and remained astigmatically neutral despite its superficial location. Agreement with GAT remained consistently good. Patients reported high acceptance and adherence and stated they would recommend the system to other glaucoma patients. In addition, the sensor enabled the assessment of both short-term and long-term IOP fluctuations.
conclusionThe EyeMate-SC enables, for the first time, high-frequency telemetric self-monitoring of IOP independent of lens status and supports therapeutic decisions based on comprehensive pressure profiles rather than single measurements. Newer system generations further extend this concept by enabling automated, continuous data acquisition with higher temporal resolution. In combination with artificial intelligence, this could enable early detection of progression-associated patterns; however, the impact on disease progression, quality of life and social participation requires further investigation.
Indexed as
Identifiers
42484855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.